SI3069728T1 - Nova imunoterapija proti več tumorjem, vključno proti nevronskim in možganskim tumorjem - Google Patents

Nova imunoterapija proti več tumorjem, vključno proti nevronskim in možganskim tumorjem

Info

Publication number
SI3069728T1
SI3069728T1 SI200931921T SI200931921T SI3069728T1 SI 3069728 T1 SI3069728 T1 SI 3069728T1 SI 200931921 T SI200931921 T SI 200931921T SI 200931921 T SI200931921 T SI 200931921T SI 3069728 T1 SI3069728 T1 SI 3069728T1
Authority
SI
Slovenia
Prior art keywords
tumors
against several
immunotherapy against
including neuronal
novel immunotherapy
Prior art date
Application number
SI200931921T
Other languages
English (en)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of SI3069728T1 publication Critical patent/SI3069728T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
SI200931921T 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno proti nevronskim in možganskim tumorjem SI3069728T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP08017921.1A EP2172212B1 (en) 2008-10-01 2008-10-13 Novel immunotherapy against several tumors including neuronal and brain tumors
US10592808P 2008-10-16 2008-10-16
EP16165070.0A EP3069728B1 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors

Publications (1)

Publication Number Publication Date
SI3069728T1 true SI3069728T1 (sl) 2019-03-29

Family

ID=40342382

Family Applications (12)

Application Number Title Priority Date Filing Date
SI200831373T SI2172211T1 (sl) 2008-10-01 2008-10-01 Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
SI200831695A SI2172212T1 (sl) 2008-10-01 2008-10-13 Nova imunoterapija proti številnim tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200931902T SI3111952T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200931464A SI2341927T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti nevronalnim in možganskim tumorjem
SI200932056T SI3124043T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200932034T SI3132801T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200931573A SI2331118T1 (sl) 2008-10-01 2009-09-28 Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
SI200931921T SI3069728T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno proti nevronskim in možganskim tumorjem
SI200932083T SI3120869T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200932064T SI3120870T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200932063T SI3106175T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200932065T SI3120868T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji

Family Applications Before (7)

Application Number Title Priority Date Filing Date
SI200831373T SI2172211T1 (sl) 2008-10-01 2008-10-01 Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
SI200831695A SI2172212T1 (sl) 2008-10-01 2008-10-13 Nova imunoterapija proti številnim tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200931902T SI3111952T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200931464A SI2341927T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti nevronalnim in možganskim tumorjem
SI200932056T SI3124043T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200932034T SI3132801T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200931573A SI2331118T1 (sl) 2008-10-01 2009-09-28 Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka

Family Applications After (4)

Application Number Title Priority Date Filing Date
SI200932083T SI3120869T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200932064T SI3120870T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200932063T SI3106175T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji
SI200932065T SI3120868T1 (sl) 2008-10-01 2009-09-28 Nova imunoterapija proti več tumorjem, vključno z nevronalnimi in možganskimi tumorji

Country Status (25)

Country Link
US (19) US8119139B2 (sl)
EP (12) EP2172211B1 (sl)
JP (10) JP5855940B2 (sl)
KR (6) KR101883426B1 (sl)
CN (3) CN106986919A (sl)
AU (2) AU2009300087B2 (sl)
BR (2) BRPI0920791B8 (sl)
CA (9) CA2936870C (sl)
CY (11) CY1116302T1 (sl)
DK (12) DK2172211T3 (sl)
EA (3) EA032437B1 (sl)
ES (12) ES2536465T3 (sl)
HK (2) HK1159526A1 (sl)
HR (12) HRP20201025T8 (sl)
HU (11) HUE031030T2 (sl)
LT (10) LT2172212T (sl)
MX (3) MX2011003540A (sl)
NZ (4) NZ603016A (sl)
PL (12) PL2172211T3 (sl)
PT (12) PT2172211E (sl)
RS (12) RS53782B1 (sl)
SI (12) SI2172211T1 (sl)
TR (2) TR201900809T4 (sl)
UA (3) UA125277C2 (sl)
WO (2) WO2010037513A1 (sl)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
CA2694808C (en) * 2007-07-27 2015-10-13 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
DK2113253T3 (da) * 2008-04-30 2010-07-19 Immatics Biotechnologies Gmbh Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012027379A2 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
MX2013006758A (es) * 2010-12-14 2013-08-01 Immatics Biotechnologies Gmbh Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
US20140154269A1 (en) * 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
WO2013040499A1 (en) * 2011-09-14 2013-03-21 Northwestern University Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
CN110711188A (zh) 2012-01-20 2020-01-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
RS62406B1 (sr) 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI777197B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（六）
PL3456339T3 (pl) 2013-08-05 2022-03-21 Immatics Biotechnologies Gmbh Nowa immunoterapia przeciwko szeregu nowotworom, takim jak rak płuc, w tym nsclc
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CN110938655A (zh) 2014-04-25 2020-03-31 蓝鸟生物公司 Mnd启动子嵌合抗原受体
JP6613526B2 (ja) * 2014-05-28 2019-12-04 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
ES2846811T3 (es) 2014-06-06 2021-07-29 Bluebird Bio Inc Composiciones de células T mejoradas
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
JP6474893B2 (ja) * 2014-11-06 2019-02-27 オーエスイー・イミュノセラピューティクス 脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法
EP3230321B1 (en) 2014-12-12 2019-08-28 Bluebird Bio, Inc. Bcma chimeric antigen receptors
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA46913B1 (fr) 2014-12-23 2021-09-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JP6985153B2 (ja) * 2015-05-06 2021-12-22 イマティクス バイオテクノロジーズ ゲーエムベーハー 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3307307A4 (en) 2015-06-09 2019-05-01 The Board of Regents of the University of Oklahoma COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE
EP3319635B1 (en) 2015-06-24 2021-04-21 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
MA42294B1 (fr) 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt) * 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
UA125817C2 (uk) 2015-08-28 2022-06-15 Імматікс Біотекнолоджіс Гмбх Пептид, придатний для лікування та/або діагностики раку
WO2017040885A1 (en) 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
KR20180107102A (ko) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 신생항원 동정, 제조, 및 용도
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN109620949A (zh) * 2016-03-13 2019-04-16 曹帅 一种用于治疗骨癌的药物组合物
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
PL3430037T3 (pl) 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
BR112018070067A2 (pt) * 2016-04-06 2019-02-12 Immatics Biotechnologies Gmbh peptídeos e combinações de peptídeos para uso em imunoterapia contra lma e outros cânceres
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
CA3034983A1 (en) * 2016-10-03 2018-04-12 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
SG10201914064QA (en) 2017-01-06 2020-03-30 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) * 2017-02-28 2018-09-07 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
TW202333779A (zh) * 2017-05-08 2023-09-01 美商磨石生物公司 阿爾法病毒新抗原載體
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
CN111465989A (zh) 2017-10-10 2020-07-28 磨石肿瘤生物技术公司 使用热点进行的新抗原鉴别
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
EP3724327A4 (en) * 2017-12-14 2022-01-12 EZY Biotech LLC SUBJECT-SPECIFIC TUMOR-INHIBITING CELLS AND THEIR USE
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
BR112020020780A2 (pt) * 2018-04-11 2021-03-02 Enterome S.A. peptídeos antigênicos para prevenção e tratamento do câncer
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
EP3946470A4 (en) * 2019-04-05 2023-05-31 Earli Inc. IMPROVED METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS
CN114207675A (zh) 2019-05-28 2022-03-18 佩治人工智能公司 用于数字病理学的用于处理图像以针对所处理的图像制备载片的***和方法
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113444149A (zh) * 2020-03-18 2021-09-28 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
US11913023B2 (en) 2020-03-31 2024-02-27 Walking Fish Therapeutics, Inc. Modified B cells and methods of use thereof
JP2023521966A (ja) * 2020-03-31 2023-05-26 ウォーキング フィッシュ セラピューティクス，インコーポレイテッド 改変ｂ細胞及びその使用方法
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
KR20220022021A (ko) 2020-08-14 2022-02-23 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2022047248A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
GB2294267B (en) 1993-06-03 1996-11-20 Therapeutic Antibodies Inc Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
EP0942748A4 (en) * 1996-07-22 2004-12-08 Univ Rockefeller ENV-GLYCOPROTEIN VACCINE FOR PROTECTION AGAINST HTLV-I AND HTLV-II INFECTIONS
AU6240798A (en) 1997-01-15 1998-08-07 Zymogenetics Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
JPH11507845A (ja) * 1997-02-13 1999-07-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経細胞付着分子スプライシング変種
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU750358B2 (en) * 1997-12-02 2002-07-18 Medarex, Inc. Cells expressing anti-Fc receptor binding components
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
US20030139327A9 (en) * 2000-01-31 2003-07-24 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055447A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
JP2004503213A (ja) 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001279581A1 (en) * 2000-09-06 2002-03-22 Friederike Muller Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7083789B2 (en) * 2000-12-04 2006-08-01 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002222108A1 (en) * 2000-12-08 2002-06-18 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
WO2004067029A1 (fr) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Procede de preparation d'un vaccin et vaccins antitumoraux
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
JP4579836B2 (ja) * 2004-01-23 2010-11-10 株式会社グリーンペプタイド 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006026569A2 (en) * 2004-08-27 2006-03-09 Northeastern University Comprehensive characterization of complex proteins at trace levels
PL1642905T3 (pl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
CN101072875B (zh) * 2004-12-07 2011-05-18 东丽株式会社 新型癌抗原肽及其用途
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
ATE461214T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
AU2007298494B2 (en) * 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2008039874A2 (en) * 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2679743A1 (en) * 2007-03-06 2008-09-12 Barry G. Arnason Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2009125394A1 (en) * 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
DK2113253T3 (da) * 2008-04-30 2010-07-19 Immatics Biotechnologies Gmbh Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
AU2015265487B2 (en) * 2014-05-28 2020-08-13 Nono Inc. Chloride salt of TAT-NR2B9c
PE20181897A1 (es) * 2016-04-21 2018-12-11 Immatics Biotechnologies Gmbh Inmunoterapia contra el melanoma y otros tipos de cancer
US20190201443A1 (en) * 2017-09-06 2019-07-04 California Institute Of Technology Signaling and antigen-presenting bifunctional receptors (sabr)

Also Published As

Publication number Publication date
EP2172211B1 (en) 2014-12-03
LT3132801T (lt) 2020-02-10
US20160376313A1 (en) 2016-12-29
JP5855940B2 (ja) 2016-02-09
JP6294914B2 (ja) 2018-03-14
US20210347822A1 (en) 2021-11-11
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
HRP20150223T1 (hr) 2015-06-05
EP3132801A1 (en) 2017-02-22
EP2341927B1 (en) 2016-05-04
DK3120870T3 (da) 2020-06-22
US10047123B2 (en) 2018-08-14
SI2172211T1 (sl) 2015-03-31
PL3132801T3 (pl) 2020-06-15
LT3106175T (lt) 2020-08-10
CA2739387A1 (en) 2010-04-08
ES2804723T3 (es) 2021-02-09
US20130309193A1 (en) 2013-11-21
US8318677B2 (en) 2012-11-27
HRP20200110T1 (hr) 2020-05-15
NZ624533A (en) 2015-09-25
JP6294913B2 (ja) 2018-03-14
CY1118702T1 (el) 2017-07-12
CA2936870A1 (en) 2010-04-08
WO2010037514A2 (en) 2010-04-08
JP2017023136A (ja) 2017-02-02
CN102170901A (zh) 2011-08-31
PL3120868T3 (pl) 2020-08-24
NZ591855A (en) 2012-11-30
EP2341927A2 (en) 2011-07-13
EP3069728B1 (en) 2018-11-14
US11208434B2 (en) 2021-12-28
ES2607460T3 (es) 2017-03-31
HUE029360T2 (en) 2017-02-28
HUE051030T2 (hu) 2021-01-28
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
BRPI0920791A2 (pt) 2019-12-10
KR101687840B1 (ko) 2016-12-19
CA2936868A1 (en) 2010-04-08
US10227381B2 (en) 2019-03-12
PT2341927T (pt) 2016-08-02
PT3120868T (pt) 2020-07-16
PT3120870T (pt) 2020-07-01
UA103202C2 (ru) 2013-09-25
EP3111952A1 (en) 2017-01-04
CA2936924C (en) 2019-07-16
US10906936B2 (en) 2021-02-02
ES2536465T3 (es) 2015-05-25
ES2584245T3 (es) 2016-09-26
US20190010190A1 (en) 2019-01-10
KR101883426B1 (ko) 2018-07-31
US20120141517A1 (en) 2012-06-07
PL3111952T3 (pl) 2019-04-30
ES2708654T3 (es) 2019-04-10
EP3120869A1 (en) 2017-01-25
PT3069728T (pt) 2019-02-13
US10047124B2 (en) 2018-08-14
ES2819244T3 (es) 2021-04-15
EP3106175B1 (en) 2020-04-01
SI3120869T1 (sl) 2020-10-30
DK3124043T3 (da) 2020-05-04
SI3120870T1 (sl) 2020-08-31
HRP20201015T1 (hr) 2020-10-16
LT3111952T (lt) 2018-12-27
JP6150859B2 (ja) 2017-06-21
US20170326217A1 (en) 2017-11-16
US8895514B2 (en) 2014-11-25
RS58443B1 (sr) 2019-04-30
CY1123098T1 (el) 2021-10-29
JP2012504393A (ja) 2012-02-23
HUE049364T2 (hu) 2020-09-28
US20210253637A1 (en) 2021-08-19
JP2012504563A (ja) 2012-02-23
EP2172212B1 (en) 2016-10-05
DK3069728T3 (en) 2019-02-25
RS58229B1 (sr) 2019-03-29
EP3111952B1 (en) 2018-10-31
US8119139B2 (en) 2012-02-21
MX338294B (es) 2016-04-11
LT2172212T (lt) 2016-11-10
ES2770090T3 (es) 2020-06-30
EP2172211A1 (en) 2010-04-07
EP3124043A1 (en) 2017-02-01
EP3120868B1 (en) 2020-04-08
HK1159526A1 (zh) 2012-08-03
EP3120868A1 (en) 2017-01-25
KR20110074894A (ko) 2011-07-04
BRPI0920759A2 (pt) 2016-03-08
JP2016145210A (ja) 2016-08-12
NZ591882A (en) 2012-12-21
ES2612466T3 (es) 2017-05-17
CA2936887C (en) 2019-11-12
CA2936869C (en) 2019-08-06
DK3111952T3 (en) 2019-01-28
SI3120868T1 (sl) 2020-08-31
HRP20201015T8 (hr) 2022-01-21
LT3120869T (lt) 2020-11-10
PT3111952T (pt) 2019-02-05
NZ603016A (en) 2014-05-30
KR20160103558A (ko) 2016-09-01
CA2739384A1 (en) 2010-04-08
HRP20161504T1 (hr) 2016-12-30
EA201100586A1 (ru) 2011-10-31
DK3106175T3 (da) 2020-06-22
SI3132801T1 (sl) 2020-03-31
EP3069728A1 (en) 2016-09-21
PT2172212T (pt) 2016-12-22
CY1116302T1 (el) 2017-02-08
DK3132801T3 (da) 2020-02-10
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
SI2172212T1 (sl) 2016-12-30
EP3120870B1 (en) 2020-04-01
DK2172212T3 (da) 2016-12-19
US9993540B2 (en) 2018-06-12
EP2172212A3 (en) 2010-04-14
JP2017018101A (ja) 2017-01-26
EP3120869B1 (en) 2020-07-22
HUE030296T2 (en) 2017-04-28
RS55543B1 (sr) 2017-05-31
DK2331118T3 (da) 2017-01-09
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
KR101756488B1 (ko) 2017-07-11
ES2710608T3 (es) 2019-04-26
US11136352B2 (en) 2021-10-05
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
RS53782B1 (en) 2015-06-30
WO2010037513A1 (en) 2010-04-08
CY1123089T1 (el) 2021-10-29
KR20200085381A (ko) 2020-07-14
EP2331118B1 (en) 2016-10-26
CA2739384C (en) 2017-05-02
LT3120870T (lt) 2020-08-10
HUE031030T2 (en) 2017-06-28
CY1121098T1 (el) 2019-12-11
HRP20201025T8 (hr) 2022-01-07
SI3124043T1 (sl) 2020-07-31
SI3111952T1 (sl) 2019-01-31
HUE049366T2 (hu) 2020-09-28
PT2331118T (pt) 2017-02-06
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
BRPI0920791B8 (pt) 2022-02-15
JP5883476B2 (ja) 2016-03-15
PT3132801T (pt) 2020-02-04
RS60381B1 (sr) 2020-07-31
US20160376314A1 (en) 2016-12-29
PL3120870T3 (pl) 2020-07-27
AU2009300088A1 (en) 2010-04-08
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
CY1123526T1 (el) 2022-03-24
RS60338B1 (sr) 2020-07-31
US8961985B2 (en) 2015-02-24
JP2017018102A (ja) 2017-01-26
EA023013B1 (ru) 2016-04-29
CY1122913T1 (el) 2021-10-29
EP3106175A1 (en) 2016-12-21
CY1121258T1 (el) 2020-05-29
AU2009300088B2 (en) 2014-09-04
CA2936869A1 (en) 2010-04-08
JP6367266B2 (ja) 2018-08-01
AU2009300087A1 (en) 2010-04-08
EP3124043B1 (en) 2020-04-29
HUE041446T2 (hu) 2019-05-28
PL2331118T3 (pl) 2017-05-31
HRP20170115T1 (hr) 2017-03-24
LT3120868T (lt) 2020-08-10
US20160355550A1 (en) 2016-12-08
SI3106175T1 (sl) 2020-08-31
PL3106175T3 (pl) 2020-08-24
US10941181B2 (en) 2021-03-09
ES2788129T8 (es) 2020-11-04
HUE042115T2 (hu) 2019-06-28
CA2936982C (en) 2019-12-03
CA2739387C (en) 2019-10-29
US20160376317A1 (en) 2016-12-29
TR201900809T4 (tr) 2019-02-21
RS55531B1 (sr) 2017-05-31
CN106986919A (zh) 2017-07-28
JP5753783B2 (ja) 2015-07-22
EP3132801B1 (en) 2019-10-30
US20160376315A1 (en) 2016-12-29
HK1161106A1 (en) 2012-08-24
CN102170901B (zh) 2015-01-07
CA2936924A1 (en) 2010-04-08
US8653035B2 (en) 2014-02-18
PT3120869T (pt) 2020-09-22
HRP20182151T1 (hr) 2019-02-08
RS60386B1 (sr) 2020-07-31
KR20180088494A (ko) 2018-08-03
US20150125478A1 (en) 2015-05-07
EP3120870A1 (en) 2017-01-25
EA032437B1 (ru) 2019-05-31
RS55043B1 (sr) 2016-12-30
CA2936982A1 (en) 2010-04-08
HRP20190202T1 (hr) 2019-03-22
US10919931B2 (en) 2021-02-16
KR20220058655A (ko) 2022-05-09
JP2016047825A (ja) 2016-04-07
MX2011003539A (es) 2011-06-20
EA201401104A1 (ru) 2015-05-29
HRP20201228T1 (hr) 2021-02-05
DK3120868T3 (da) 2020-06-22
MX2011003540A (es) 2011-06-20
US20130004456A1 (en) 2013-01-03
KR102133402B1 (ko) 2020-07-14
JP2014239681A (ja) 2014-12-25
LT3069728T (lt) 2019-02-11
KR102392070B1 (ko) 2022-04-29
DK2341927T3 (en) 2016-08-15
CY1122677T1 (el) 2021-03-12
PT3106175T (pt) 2020-07-01
US10046037B2 (en) 2018-08-14
DK3120869T3 (da) 2020-08-10
CN102170900A (zh) 2011-08-31
US20210261614A1 (en) 2021-08-26
PL2341927T3 (pl) 2016-11-30
JP6214066B2 (ja) 2017-10-18
EP2331118A1 (en) 2011-06-15
CA2936887A1 (en) 2010-04-08
HRP20200988T1 (hr) 2020-10-16
HUE050428T2 (hu) 2020-12-28
PT2172211E (pt) 2015-03-09
WO2010037514A3 (en) 2010-06-03
PL3124043T3 (pl) 2020-07-27
JP2017000148A (ja) 2017-01-05
HRP20160915T1 (hr) 2016-10-07
CA2936920A1 (en) 2010-04-08
US20160376316A1 (en) 2016-12-29
HUE049367T2 (hu) 2020-09-28
RS60385B1 (sr) 2020-07-31
US20210238227A1 (en) 2021-08-05
PL2172212T3 (pl) 2017-04-28
LT2331118T (lt) 2016-12-27
CA2936920C (en) 2019-12-03
TR201900852T4 (tr) 2019-02-21
CN102170900B (zh) 2016-10-26
DK2172211T3 (en) 2015-02-16
SI2331118T1 (sl) 2017-01-31
AU2009300087B2 (en) 2014-09-04
UA110599C2 (uk) 2016-01-25
US20100158931A1 (en) 2010-06-24
ES2802227T3 (es) 2021-01-18
CY1123113T1 (el) 2021-10-29
KR20110082155A (ko) 2011-07-18
CA2936870C (en) 2019-11-26
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
PL2172211T3 (pl) 2015-05-29
JP2017029135A (ja) 2017-02-09
PT3124043T (pt) 2020-05-12
HUE047365T2 (hu) 2020-04-28
HRP20150223T8 (hr) 2015-07-03
CY1119744T1 (el) 2018-06-27
JP6297632B2 (ja) 2018-03-20
HRP20200722T1 (hr) 2020-10-16
BRPI0920791B1 (pt) 2022-01-18
EP2172212A2 (en) 2010-04-07
CA2936868C (en) 2019-10-22

Similar Documents

Publication Publication Date Title
HRP20201015T8 (hr) Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga